JLHL Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹365 Cr
verified against source
Revenue YoY
9.8%
reported change
EBITDA
₹83.44 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jupiter Life Line Hospitals reported Q3 FY26 consolidated total income of 365.3 crores (up 9.8% YoY), with EBITDA at 83.44 crores (margin 22.8%) and PAT at 42.5 crores, which declined 18.7% YoY due to a one-time 6.4 crore labor court provision. The 9-month performance shows revenue of 1,111.9 crores (+15.1% YoY) and EBITDA of 254 crores (+15.2% YoY). Key positives include the Dombivli hospital completing ahead of schedule (500 beds, 425 crore capex) with inauguration slated for February 15th, though management cautions of EBITDA drag for ~2 years and significantly higher depreciation going forward. Pune South construction has commenced while Mira Road awaits regulatory approval. ARPOB for 9M stands at 66,800 with 61.9% occupancy. The management signaled long-term confidence but declined to provide ARPOB targets, indicating growth would track inflation for mature hospitals while newer facilities ramp up. No specific guidance on margin trajectory was provided.
Colored figures show movement against the previous available record.
Guidance to track
- The new Dombivli hospital is expected to break even by end of year two from opening, with typical ramp-up following the company's established 2-3 year stabilization period for new facilities.
- Beginning next quarter, consolidated depreciation will be significantly higher due to Dombivli capitalization, with EBITDA drag expected for approximately 2 years before the new hospital starts contributing.
- Management explicitly stated they do not track ARPOB internally and have no targets. Mature hospitals are expected to grow ARPOB in line with inflation, while newer hospitals will see faster growth until maturity.
- Pune South project is in early construction stage (excavation complete, basement work underway) with target launch in calendar year 2028.
Risks flagged
- Management explicitly warned of EBITDA drag on consolidated numbers for approximately 2 years as Dombivli ramps up. Additionally, significantly higher depreciation charges beginning next quarter will impact profitability metrics.
- Analyst pressed on long-term ARPOB growth versus cost inflation (particularly nurse/doctor costs rising faster than general inflation) given ARPOB is linked to insurance inflation. Management deflected, calling it 'too much astrology' to predict.
- First quarter of single-digit revenue growth (9.8%) was flagged by an analyst. Management attributed it to capacity constraints at mature hospitals (Thane, Pune) and quarterly variability, not demand or payer issues.
- Analyst raised concerns about competitors (specifically Reliance Hospital) offering exclusive contracts to star doctors, potentially affecting Jupiter's ability to attract top talent. Management acknowledged the practice but stated it is not sustainable long-term.
Key quotes
- Healthcare cannot be monitored on quarter to quarter. Each hospital has finite capacity. Very soon I would hope that all the mature hospitals are able to report zero growth because they are already at maturity. So the growth eventually comes from new and upcoming hospitals where you start from zero.
- On Pune South: 'Construction is begun. We have just started the basement work. As we have said, we are slated to begin it sometime in calendar year 28 and we are reasonably sure to achieve that target. Capex so far maybe less than 50 crore so far.'
- On margin trajectory: 'How the macroeconomics will play out? How the wages will happen over the next several years? What will be the impact of GST? How will taxation play out? Too much of astrology is difficult to do.' - declining to provide specific long-term margin guidance.
Research modules